Search

Dynamic computer simulation data are compared for the first time with CE data obtained with a laboratory made system comprising an array of 8 contactless conductivity detectors (C(4) Ds). The experimental setup featured a 50 μm id linear polyacrylamide (LPA) coated fused-silica capillary of 70 cm length and a purpose built sequential injection analysis manifold for fluid handling of continuous or discontinuous buffer configurations and sample injection. The LPA coated capillary exhibits a low EOF and the manifold allows the placement of the first detector at about 2.7 cm from the sample inlet. Agreement of simulated electropherograms with experimental data was obtained for the migration and separation of cationic and anionic analyte and system zones in CZE configurations in which EOF and other column properties are constant. For configurations with discontinuous buffer systems, including ITP, experimental data obtained with the array detector revealed that the EOF is not constant. Comparison of simulation and experimental data of ITP systems provided the insight that the EOF can be estimated with an ionic strength dependent model similar to that previously used to describe EOF in fused-silica capillaries dynamically double coated with Polybrene and poly(vinylsulfonate). For the LPA coated capillaries, the electroosmotic mobility was determined to be 17-fold smaller compared to the case with the charged double coating. Simulation and array detection provide means for quickly investigating electrophoretic transport and separation properties. Without realistic input parameters, modeling alone is not providing data that match CE results.

In addition to the monographs which have been published recently by the working group "Drug Monitoring" of the Swiss Society of Clinical Chemistry (SSCC) [1, 2], new monographs have been written. The aim of these monographs is to provide an overview on the information which is important for the request and interpretation of the results. Therefore, the targeted readers are laboratory health professionals and the receivers of the reports. In this series, aminoglycoside as well as glycopeptide antibiotics are presented. In addition, two antimycotic drugs, which are regularly quantified in sera of intensive care patients, are described. Also, the monograph on mebendazole is shown. This drug is often used in high doses for the treatment of infections with Echinococcus multilocularis for which the measurement of drug concentrations in serum is recommended. Information on the indication for therapeutic drug monitoring (TDM), protein binding, metabolic pathways and enzymes involved, elimination half-life and elimination routes, and therapeutic or toxic concentrations is provided. Because pre-analytical considerations are of particular importance for therapeutic drug monitoring, there is also information given at which time the determination of the drug concentration is reasonable and when steady-state concentrations are reached after changing the dose. Furthermore, the stability of the drug and its metabolite(s) after blood sampling is described. For readers with a specific interest, references to important publications are provided. The number of the monographs will be continuously increased. The updated files are presented on the homepage of the SSCC (www.sscc.ch). We hope that these monographs are helpful for the better handling of therapeutic drug monitoring and we are looking forward to comments by the readers. In Ergänzung zu den in den letzten Jahren publizierten Arzneimittelmonographien der Arbeitsgruppe Medikamente der Schweizerischen Gesellschaft für Klinische Chemie (SGKC) [1, 2], sind nun weitere Monographien erstellt worden. Ziel dieser Monographien ist es, dem Labormediziner bzw. dem Empfänger der Befunde eine Übersicht über die wichtigsten Informationen zu geben, die für die Veranlassung einer Analyse bzw. für die Interpretation der Resultate hilfreich sind. In dieser Serie werden die Aminoglykosid- und Glykopeptidantibiotika präsentiert, wie auch zwei Antimykotika, bei denen vor allem bei Intensivpatienten immer häufiger Messungen im Serum durchgeführt werden. Zusätzlich wird die Monographie von Mebendazol präsentiert, das im Rahmen der Infektionen mit Echinococcus multilocularis (Fuchsbandwurm) in hohen Dosen verabreicht und im Serum bestimmt wird. In den einzelnen Monographien werden klinisch pharmakologische Angaben wie zum Beispiel Indikation für das Therapeutic Drug Monitoring (TDM), Proteinbindungen, Metabolisierungswege und daran beteiligte Enzyme, Halbwertszeiten und Eliminationswege der Muttersubstanz, sowie Informationen zu therapeutischen bzw. toxischen Bereichen, zur Verfügung gestellt. Da die Präanalytik gerade beim Therapeutic Drug Monitoring eine wichtige Rolle spielt werden auch hier Angaben gemacht zu welchem Zeitpunkt eine Bestimmung der Arzneimittelkonzentration sinnvoll ist und wann, nach einer Dosisänderung, der steady-state erreicht ist. Außerdem werden Angaben über die Stabilität der Medikamente bzw. ihrer Metaboliten nach der Blutentnahme gemacht. Für die interessierten Leser sind die verwendeten Referenzen als Zitate aufgeführt. Die Zahl der Monographien wird fortlaufend ergänzt. Die aktuellsten Versionen der Monographien sind auf der Homepage der SGKC abrufbar (www.sscc.ch). Wir hoffen, dass diese Monographien im Umgang mit dem Therapeutic Drug Monitoring hilfreich sein werden und freuen uns über Kommentare und Bemerkungen.

In 1995 the working group "Drug Monitoring" of the Swiss Society of Clinical Chemistry (SSCC) has already published a printed version of drug monographs, which are now newly compiled and presented in a standardised manner. The aim of these monographs is to give an overview on the most important informations that are necessary in order to request a drug analysis or is helpful to interpret the results. Therefore, the targeted audience are laboratory health professionals or the receivers of the reports. There is information provided on the indication for therapeutic drug monitoring, protein binding, metabolic pathways and enzymes involved, elimination half life time and elimination routes as well as information on therapeutic or toxic concentrations. Because preanalytical considerations are of particular importance for therapeutic drug monitoring, there is also information given at which time the determination of the drug concentration is reasonable and when steady-state concentrations are reached after changing the dose. Furthermore, the stability of the drug and its metabolite(s), respectively, after blood sampling is described. For readers with a specific interest, references to important publications are given. The number of the monographs will be continuously enlarged. The updated files are presented on the homepage of the SSCC (www.sscc.ch).